285 related articles for article (PubMed ID: 32238381)
21. Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.
Long Y; Tao H; Karachi A; Grippin AJ; Jin L; Chang YE; Zhang W; Dyson KA; Hou AY; Na M; Deleyrolle LP; Sayour EJ; Rahman M; Mitchell DA; Lin Z; Huang J
Cancer Res; 2020 Feb; 80(3):499-509. PubMed ID: 31723000
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
[TBL] [Abstract][Full Text] [Related]
23. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
24. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
25. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
26. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
[TBL] [Abstract][Full Text] [Related]
27. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
[TBL] [Abstract][Full Text] [Related]
28. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
29. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.
Xu A; Zhang L; Chen Y; Lin Z; Li R
Cancer Immunol Immunother; 2017 Feb; 66(2):181-192. PubMed ID: 27872951
[TBL] [Abstract][Full Text] [Related]
32. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.
Gu M; Zhou X; Sohn JH; Zhu L; Jie Z; Yang JY; Zheng X; Xie X; Yang J; Shi Y; Brightbill HD; Kim JB; Wang J; Cheng X; Sun SC
Nat Immunol; 2021 Feb; 22(2):193-204. PubMed ID: 33398181
[TBL] [Abstract][Full Text] [Related]
33. Tim-4
Chow A; Schad S; Green MD; Hellmann MD; Allaj V; Ceglia N; Zago G; Shah NS; Sharma SK; Mattar M; Chan J; Rizvi H; Zhong H; Liu C; Bykov Y; Zamarin D; Shi H; Budhu S; Wohlhieter C; Uddin F; Gupta A; Khodos I; Waninger JJ; Qin A; Markowitz GJ; Mittal V; Balachandran V; Durham JN; Le DT; Zou W; Shah SP; McPherson A; Panageas K; Lewis JS; Perry JSA; de Stanchina E; Sen T; Poirier JT; Wolchok JD; Rudin CM; Merghoub T
Cancer Cell; 2021 Jul; 39(7):973-988.e9. PubMed ID: 34115989
[TBL] [Abstract][Full Text] [Related]
34. Cytokine-like molecule CCDC134 contributes to CD8⁺ T-cell effector functions in cancer immunotherapy.
Huang J; Xiao L; Gong X; Shao W; Yin Y; Liao Q; Meng Y; Zhang Y; Ma D; Qiu X
Cancer Res; 2014 Oct; 74(20):5734-45. PubMed ID: 25125657
[TBL] [Abstract][Full Text] [Related]
35. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
[TBL] [Abstract][Full Text] [Related]
36. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
Ko E; Luo W; Peng L; Wang X; Ferrone S
Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
[TBL] [Abstract][Full Text] [Related]
37. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
[TBL] [Abstract][Full Text] [Related]
38. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia inducible factor-1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer.
Zhu H; Zhang S
J Cell Biochem; 2018 Sep; 119(9):7707-7718. PubMed ID: 29904944
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
